Physician profile
Robert H Blee
NPI 1730193301
$2,449.88
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $347 · 2021: $617 · 2022: $504 · 2023: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $442.10 | 2019-2023 | |
| Novo Nordisk INC | $294.86 | 2019-2023 | Ozempic, Saxenda, Wegovy |
| Amgen INC. | $219.87 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $175.99 | 2021-2023 | Qulipta, Ubrelvy |
| Bausch Health US, LLC | $174.14 | 2019-2023 | Aplenzin, Wellbutrin |
| Astrazeneca Pharmaceuticals Lp | $119.83 | 2019-2023 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $84.87 | 2021 | |
| Merck Sharp & Dohme LLC | $80.08 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $77.97 | 2019 | |
| Esperion Therapeutics, INC. | $61.30 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $56.25 | 2019-2021 | |
| Astellas Pharma US INC | $48.37 | 2021-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.42 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.38 | 2019-2023 | Xifaxan |
| Horizon Therapeutics Plc | $44.47 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.88 | 2022 | |
| Eisai INC. | $41.27 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.15 | 2019-2023 | Camzyos |
| Sanofi-Aventis U.S. LLC | $41.02 | 2019 | |
| Fidia Pharma USA INC. | $40.05 | 2022 | |
| Allergan, INC. | $36.18 | 2019-2020 | |
| Radius Health, INC. | $26.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.04 | 2019 | |
| Lilly USA, LLC | $21.53 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $19.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.41 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $18.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.43 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $15.13 | 2021 | |
| Genentech USA, INC. | $12.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Blee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.